Gilead Sciences, Inc. $GILD Shares Acquired by Focus Partners Advisor Solutions LLC

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Gilead Sciences, Inc. by 62.7%, owning 8,064 shares valued at approximately $904,000.
• Gilead Sciences received multiple analyst upgrades, including a "strong-buy" rating from Daiwa America and a revised price target of $128.00.
• The company declared a quarterly dividend of $0.79 per share, representing an annualized yield of 2.8%, with an ex-dividend date on September 15th.

Focus Partners Advisor Solutions LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 62.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,064 shares of the biopharmaceutical company's stock after acquiring an additional 3,107 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Gilead Sciences were worth $904,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences in the first quarter worth $25,000. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter worth $29,000. Colonial Trust Advisors raised its position in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on GILD shares. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares of the company's stock, valued at $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer directly owned 595,725 shares of the company's stock, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

GILD stock traded up $0.83 during trading on Monday, hitting $115.88. The stock had a trading volume of 13,156,212 shares, compared to its average volume of 8,095,955. The stock has a market capitalization of $143.79 billion, a P/E ratio of 23.08, a PEG ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a twelve month low of $78.36 and a twelve month high of $121.83. The company's 50-day moving average price is $113.59 and its two-hundred day moving average price is $109.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the prior year, the company posted $2.01 earnings per share. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.